Trial Profile
Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from Zidovudine- containing backbone to Truvada in HIV-1-infected patients on highly active antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine; Zidovudine
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms RECOMB
- Sponsors Gilead Sciences
- 08 Mar 2012 Results assessing the effects of treatment on the fat mass ratio presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 22 Jul 2009 Long-term, 72-week results have been presented at IAS 2009.
- 10 Feb 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.